controversi debat amid
focu otezla integr new product growth
close acquisit otezla expect focu stock
larg integr asset immunolog inflamm
franchis well abil on-going new product launch repatha even
aimovig amgen biosimilar boost growth profil still see
growth peer revenu compound-annual-growth-rate vs peer averag
view otezla acquisit step right direct boost
revenu ep guidanc previous guid midpoint
previou midpoint result updat po
reiter neutral rate await asset boost amgen
growth profil peer level
acquisit behind us highlight remain controversi
outstand question
new product cycl show mix perform especi slow launch
aimovig repatha amid previous high growth expect
could see neulasta eros rate acceler biosimilar
approv could eros stabil even taper sticki onpro
kra data look solid nsclc effect minim
wherea competitor saw higher respons rate
smooth otezla integr could see meaning
synergi acquisit kick-in
strong amgen biosimilar perform exceed expect
enough boost growth profil amid biosimilar eros next leg
tezepelumab clinic profil asthma impress
replic phase launch expect meaning
stori next coupl year
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu nearli
neutral rate base peer growth
driven declin legaci product revenu
quit met grow new product launch
interest oncolog pipelin need de-risk
strong cash flow allow addit
share buyback dividend payment busi
po per share valu use sum part npv
analysi market pipelin drug assum rang
weight averag cost capit wacc approv drug
pipelin drug base stage approv product market life pipelin
develop termin growth rate new launch legaci
product po also reflect net cash
upsid risk price object slower expect eros neulasta
esa franchis faster growth aimovig repatha even prolia
better expect clinic trial result oncolog pipelin
downsid risk price object faster expect revenu eros
legaci brand slower expect growth new drug launch clinic trial
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
